Press release
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:\n\n31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022) – March 30-April 3, 2022\n\nTitle: Pharmacokinetics and Safety of JNJ-73763989, an RNA Interference Therapy for Hepatitis B Virus, in Moderately Hepatically Impaired Participants\nAuthors: Thomas N. Kakuda, et al.\n\nTitle: Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants\nAuthors: Haiyan Li, et al.\n\nTitle: Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors\nAuthors: Edward Gane, et al.\n\nAmerican Association for Cancer Research Annual Meeting 2022 (AACR) – April 8-13, 2022\n\nTitle: Targeting HIF2a with siRNA: From preclinical models to the clinic\nAuthors: Yuanqing Ma, et al.\n\nDIA/FDA's Oligonucleotide-based Therapeutics Conference (Oligo22) – April 25-27, 2022\n\nTitle: Short Interfering RNA JNJ-3989 Combination Therapy\nPresenter: Michael Biermer, Senior Director, Clinical Development, Janssen Pharmaceuticals\n\nTitle: ARO-HIF2 Evaluated in Clear Cell Renal Cell Carcinoma Ph1b Clinical Trial\nPresenter: James Hamilton, Senior Vice President, Discovery and Translational Medicine, Arrowhead Pharmaceuticals\n\nA copy of the presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.\n\nAbout Arrowhead Pharmaceuticals\n\nArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.\n\nFor more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Co...